NEW YORK, March 2, 2026, 08:28 EST — Premarket
- XRAY drops 2.5% premarket, giving back some of Friday’s sharp gains
- Mizuho bumped its price target higher, with a handful of other firms also tweaking their targets upward after the results.
- Investors are sizing up restructuring payouts while facing a risk-off market, with U.S. data still to come.
Dentsply Sirona (XRAY.O) dropped 2.5% to $14.31 in premarket trading as of 8:24 a.m. ET. Shares had closed at $14.68 on Friday, having rallied 15.5%. Mizuho bumped its price target up to $16 from $14 while sticking with a Neutral rating—yet the stock edged lower. Investing.com
The stock is clinging to last week’s optimism, even as sentiment sours across the wider market. U.S. stock index futures dropped over 1% Monday, weighed by concerns about a deepening Middle East conflict. Oil prices surged—hardly a combination that encourages risk-taking. Reuters
Why it’s front and center: Dentsply is deep in a turnaround, with investors weighing if trimmed costs and a new capital plan can counter sluggish demand for pricier dental procedures. Shares have swung sharply, and the stock takes a hit every time fresh macro news lands.
Several analysts have raised their price targets after the company posted fourth-quarter numbers, Benzinga said. Michael Petusky at Barrington Research went with an Outperform and moved his target to $17, while Elizabeth Anderson at Evercore ISI kept an In-Line but bumped her target to $15. The same report mentioned the company’s 2026 guidance: adjusted earnings per share between $1.40 and $1.50, and sales ranging from $3.5 billion to $3.6 billion. Benzinga
Mizuho lowered its own earnings forecasts and pointed to a planned double-digit jump in R&D spending for this year, with management having already signaled that move. The firm called the new $120 million restructuring initiative a plus, but said those savings are slated for reinvestment in the company’s “Return-to-Growth” strategy—starting with a push into dental implants. Investing.com
The company’s latest annual filing details the shift: no more quarterly dividends after the March 31 quarter, plus a restructuring set for 2026 that’s projected to cut $120 million in costs each year. To pull that off, they’re budgeting $55 million to $65 million in one-time charges—mostly cash—across 2026 and 2027. Part of the savings, according to the filing, is earmarked for things like innovation and training. Securities and Exchange Commission
Some investors balk at the reinvestment push. Sure, ramped-up R&D spending can shore up a pipeline, but it’s a tradeoff—if demand lags, those bigger outlays bite into near-term margins.
Dentsply’s reach spans dental equipment and consumables, overlapping segments where names like Envista and Henry Schein also operate. Align Technology, meanwhile, remains the clear aligner heavyweight. For XRAY, traders are eyeing implant execution, gauging if it can boost U.S. results without dragging on other regions.
Downside risk looks straightforward: if restructuring ends up costing more than projected and savings are slow to kick in, dentists may just keep putting off elective work—especially if patients remain wary. Volatile markets only stretch out the wait.
The next hurdle won’t come from earnings — it’s on the calendar. ISM drops its manufacturing PMI at 10:00 a.m. ET Monday, with the February U.S. Employment Situation report lined up for Friday, March 6 at 8:30 a.m. ET. Both releases have the potential to move risk assets this week. Institute for Supply Management
